Patient reported outcomes exploring quality of life in PROC and novel therapeutics: mirvetuximab in recurrent ovarian cancer-Recording

Video Transcription

Video Summary

The IGCS Educational Session, featuring Flora Backus and Larissa Meyer, focuses on patient-reported outcomes (PROs) and their impact on quality of life for individuals with recurrent ovarian cancer, particularly in the context of platinum-resistant and novel therapeutics like mirvotuximab. The discussion underscores the significance of PROs in clinical trials, highlighting how they can offer valuable insights into treatment effectiveness and decision-making, improve health outcomes, and provide regulatory labels for new drugs.<br /><br />Meyer emphasizes the importance of collecting direct patient feedback to assess symptom management and treatment tolerability, especially in palliative care. The session reviews findings from various trials, illustrating how PROs contribute to understanding therapeutic impacts on patients, particularly regarding quality of life and survival outcomes in ovarian cancer treatments.<br /><br />The importance of considering grade 2 adverse events in PROs is addressed, as these can significantly affect patients' daily lives. The session concludes with a call for deeper integration of PRO data in research and practice, advocating for a collaborative approach between patients and healthcare providers to enhance treatment strategies.

Keywords

patient-reported outcomes

ovarian cancer

quality of life

platinum-resistant

mirvotuximab

clinical trials

adverse events